DR. CHARLES GRUENWALD JR., M.D.

Plain English
This study tested a new drug called SRX246 in patients with early symptoms of Huntington's disease who experience irritability. Researchers found that SRX246 was safe and well tolerated, with 82 out of 106 patients completing the trial, and it showed promise for treating aggressive and impulsive behaviors. Importantly, the drug did not worsen symptoms like apathy or suicidal thoughts. Who this helps: This benefits patients with Huntington's disease and their doctors by offering potential new treatment options for irritability and aggression.

Plain English
The study looked at how a procedure called left atrial decompression helped children with severe heart failure who were on a machine called venoarterial extracorporeal membrane oxygenation (VA ECMO) from 2005 to 2011. Out of 178 patients, 12.9% (23 children) underwent left atrial decompression, and 70% of them had this procedure done right when they started VA ECMO. Of the patients who had this decompression, 57% survived to leave the intensive care unit and 52% were discharged from the hospital, indicating that doing this procedure early may improve recovery chances. Who this helps: This benefits children with severe heart issues and their doctors.

Plain English
This study looked at how advancements in technology and the development of skilled teams at a hospital improved the use of extracorporeal membrane oxygenation (ECMO), a life-saving treatment for children with severe heart and lung issues. Over nearly 25 years, there were 576 ECMO treatments for 534 patients, with survival rates varying. Notably, survival was 45% for cardiac ECMO patients but only 33% overall, and the most common complications were bleeding (about 14%), kidney issues (11%), and lung problems (7%). These findings highlight the importance of both technological improvements and training for teams to enhance patient outcomes. Who this helps: This helps patients needing ECMO treatment and the medical teams caring for them.

Plain English
This study looked at how heart surgeons in North America manage the heart during pediatric heart surgeries, specifically focusing on the techniques and types of solutions they use to protect the heart. They surveyed 122 surgeons and analyzed 56 responses, finding that 86% preferred blood-based solutions for heart protection, while 93% used cold solutions. Key findings also revealed that surgeons using certain solutions like del Nido and Custodiol tend to provide protection for longer periods without needing repeat doses. Who this helps: This research benefits pediatric heart surgeons by providing insights into current practices and guiding them on effective heart protection strategies during surgery.

Plain English
This study looked at how well a heart support device called the Berlin Heart EXCOR worked for children needing help before a heart transplant, focusing on 15 patients treated from 2004 to 2008. The results showed that most patients had significant heart issues, with a support period averaging 29 days, and while two children died, all others were doing well and were healthy at follow-up. This matters because it highlights that this device can safely help young patients with severe heart conditions until they can receive a transplant, with manageable complications. Who this helps: This benefits children with severe heart problems and their families.

Plain English
This study looked at how effective extra-corporeal life support (ECLS) is for children after heart surgery, examining the experiences of 180 patients over 17 years. They found that 68 out of the 180 patients (38%) left the hospital alive after receiving ECLS, with an average support duration of 3 days for survivors compared to 5 days for those who did not survive. The research highlights that while ECLS helps many young patients, risks such as kidney problems, neurological issues, and longer ECLS times can lower survival chances, suggesting that addressing these complications early could improve outcomes. Who this helps: This research benefits pediatric patients undergoing heart surgery and their healthcare providers.

Plain English
This study looked at using two medical devices, the Berlin Heart EXCOR and the Novalung, together to help animals with heart and lung failure. The researchers found that while the Novalung slightly lowered blood pressure by an average of 13 mm Hg, it did not interfere with blood flow from the heart pump, indicating that the combination of these devices worked well together. This matters because it could provide a safer alternative to the current lung treatment, ECMO, which carries significant risks. Who this helps: This benefits patients with both heart and lung failure.

Plain English
This study looked at the use of a method called extracorporeal cardiopulmonary resuscitation (ECPR) in children who went into cardiac arrest and did not respond to standard treatments. Among 80 children reviewed, 34% survived to leave the hospital, and 30% had a good recovery without major brain damage. The study found that no specific factors could predict who would have a better outcome, meaning that all patients could benefit from this aggressive life-saving approach. Who this helps: This helps children facing severe cardiac emergencies and their families.

Plain English
This study looked at the outcomes of 25 infants with a single ventricle heart condition who received life support after heart surgery. The researchers found that about 76% of the babies survived the immediate post-support phase, but only 44% were discharged from the hospital, with significant risks for those suffering from multiorgan failure or severe infections. These findings highlight the critical need for improved interventions and support for these vulnerable patients to increase their chances of recovery and survival. Who this helps: This helps infants with single ventricle heart defects and their families.

Plain English
This study looked at how using extracorporeal membrane oxygenation (ECMO) in children with severe breathing and heart problems affects their health and healthcare costs. It found that while some children survive after using ECMO, many of them face long-term health issues and need a lot of ongoing medical care, which leads to higher healthcare expenses. Understanding these outcomes helps doctors make better decisions about using ECMO for children with serious conditions. Who this helps: This helps doctors and healthcare planners.

Plain English
This study explored heart transplants in infants with serious heart conditions who previously faced high mortality while waiting for compatible donors. Researchers at the Hospital for Sick Children in Toronto found that allowing heart transplants regardless of blood type compatibility reduced the waiting list death rate from 58% to just 10%. Using a special technique, they achieved an impressive 87% survival rate among the infants who received these transplants, helping to fill the critical gap in available donor hearts. Who this helps: This benefits infants with serious heart diseases and their families.

Plain English
This review looked at the use of a drug called aprotinin in children who had heart surgery involving a heart-lung machine, specifically from 1993 to 2000. It found that using high doses of aprotinin can lead to less post-operative blood loss and shorter hospital stays, particularly in very young patients, while no significant differences were noted in blood loss during initial surgeries. This matters because it can improve recovery for young patients undergoing complex heart procedures. Who this helps: This helps pediatric patients undergoing heart surgery and their families.

Plain English
This study looked at how well a device measuring heparin levels in whole blood (WHBC) works compared to the standard method of measuring heparin levels in plasma (anti-Xa) in children under one year old who are undergoing heart surgery with a heart-lung machine. Researchers found no significant correlation between the two methods, meaning the whole blood readings weren't reliable indicators of heparin levels (with correlation scores of r = 0.113 and r = -0.247) in this patient group. This matters because incorrect heparin monitoring could affect patient safety and surgical outcomes, indicating a need for better testing methods in young children during these procedures. Who this helps: This helps doctors and medical teams working with young patients undergoing heart surgeries.

Plain English
This study looked at 31 children who had severe heart problems and needed a special treatment called ECMO, which helps support heart function. The researchers found that 45% of the children were able to stop using ECMO successfully, but 70% could be helped if those with specific heart defects after surgery were excluded. Importantly, the study revealed that using ECMO for more than 6 days didn’t improve outcomes, meaning quick intervention is crucial for recovery. Who this helps: This information benefits doctors treating pediatric heart patients and improves care strategies for children facing severe heart issues.

Plain English
This study looked at a new way to give a drug called 8-methoxypsoralen (EX-8-MOP) during a treatment called extracorporeal photochemotherapy (EP) for skin diseases like cutaneous T-cell lymphoma and rheumatoid arthritis. Researchers found that by using EX-8-MOP, they could achieve stable drug levels with much smaller amounts—only 1/250 to 1/500 of the typical oral dose—and without the side effects associated with taking the drug by mouth. This is important because it simplifies the treatment process and may enhance its effectiveness. Who this helps: Patients with skin conditions treated with photopheresis, like cutaneous T-cell lymphoma and rheumatoid arthritis.

Plain English
This study looked at how a device called extracorporeal membrane oxygenation (ECMO), used for very sick babies, affects the levels of important medications in their blood. Researchers found that when using a new ECMO circuit, certain drugs like vancomycin and morphine were reduced significantly—by 36% and 36%, respectively. However, in a used ECMO system, the reduction was much less, with morphine dropping only by 16%. This is important because it shows that the type of ECMO system can change how patients respond to their medications, which could mean doctors need to adjust dosages for babies on ECMO. Who this helps: This helps doctors and healthcare providers who treat critically ill infants on ECMO.

Plain English
This study looked at how two different machines measure the effects of heparin, a blood thinner, in children undergoing heart surgery with cardiopulmonary bypass (CPB). Researchers found that the older machine (Hemochron) showed significantly higher readings of clotting times than the newer machine (HemoTec), which could lead doctors to give more heparin than necessary—94% of readings from the old machine were above the safe threshold compared to only 27% from the new one. Understanding these differences is important because improper dosing of heparin can increase the risk of complications during surgery. Who this helps: This helps doctors and children undergoing heart surgery by ensuring the right amount of heparin is given.

Plain English
This study focused on a new way to measure how well the thumb can move in a circular motion after a surgical procedure called opponensplasty. Researchers found that the range of thumb movement improved significantly, indicating that patients could use their hands for tasks they couldn't do before. This method is important because it provides a clear way to evaluate thumb function and the success of the surgery. Who this helps: This helps patients recovering from thumb surgery.